Plain language summary of TALAPRO-2 study: Talazoparib plus enzalutamide vs. placebo plus enzalutamide for advanced prostate cancer
This plain language summary of publication article (PLSP) from Future Oncology, details the TALAPRO-2 clinical trial results, which tested talazoparib plus enzalutamide as the first treatment for adults with metastatic castration-resistant prostate cancer. The study compared this combination to a placebo plus enzalutamide.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial’ and was published in The Lancet.
Visit The Lancet using the link to read the original article.